Table 3 The reason for discontinuation of the tumour necrosis factor alpha inhibitors and the duration until discontinuation of the two groups that were included in the drug survival analysis
| Â | Â | All patients (n = 921) | Axial group (n = 737) | Extra-axial group (n = 184) | p-value |
|---|---|---|---|---|---|
Inefficacy | n (%) | 122 (13.2) | 87 (11.8) | 35 (19.0) | 0.014 |
Duration (years) | 1.22 (1.20) | 1.30 (1.28) | 1.01 (0.97) | 0.181 | |
Adverse events | n (%) | 95 (10.3) | 72 (9.8) | 23 (12.5) | 0.337 |
Duration (years) | 0.89 (0.92) | 0.97 (0.98) | 0.61 (0.67) | 0.049 |